EXPERIENCE OF IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION PATIENTS MANAGEMENT IN URAL FEDERAL DISTRICT: FEATURES OFOUTPATIENT-HOSPITAL INTERACTIONS

Idiopathic pulmonary arterial hypertension (IPAH) is a severe chronic and rapidly progressive disease with increasing pulmonary vascular resistance (PVR) due to the ongoing pathogenic processes in the vascular wall that lead to obstruction of small pulmonary arteries and arterioles. IPAH takes a small part in the structure among all forms of pulmonary hypertension (PH), the median survival of patients with IPAH before any PAH-specific therapy became available were about 2,8 years, and the average time from the manifestation of the disease to its diagnosis took 2-3 years. This article is an attempt to present an unified data of adult patients with IPAH in Ural Federal district, and describe PH patients medical care service. The article presents the experience of PH Medical Centers across Ural Federal District.

pulmonary arterial hypertension (PAH), idiopathic pulmonary arterial hypertension (IPAH), registry, epidemiology, treatment

1. Data of the site «Ural Federal District». Available by reference: http://uralfo.gov.ru/ (available on 29.01.2019).

2. Chazova IY, Avdeev SN, Volkov AV, Martynyuk TV, Nakonechnikov SN et al. Clinical Guidlines on the diagnosis and treatment of Pulmonary Hypertension. Therapeutic Archive 2014; 9: 4-23.

3. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat. Biotechnol. 2013; 31: 1064.

4. Martynyuk TV et al. Pulmonary Hypertension: diagnosis and treatment. Moscow, 2018, 148.

5. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263–73.

6. N.A. Cherepanova, D.V. Duplyakov, V.P. Kuzmi et al. Experience of outpatient center for pulmonary hypertension in the Samara region. Complex Issues of Cardiovascular Diseases. 2018; 7 (1): 108-113. DOI: 10.17802/2306-1278-2018-7-1-108-113.

7. Ghofrani HA, Voswinckel R, Gall H et al. Riociguat for pulmonary hypertension. Future Cardiol 2010; 6: 155-166.

8. Montani et al. Pulmonary arterial hypertension. Orphanet Journal of Rare Diseases, vol. 8, p. 97, 2013.

9. Hemnes AR, Champion HC. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Exp Rev CardiovascTher 2006; 4: 293–300.

10. Galie N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). EurRespir J. 2015; 46(4): 903-75.

11. M. M. Hoeper et al. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. RespiratoryMedicine (2016), http://dx.doi.org/10.1016/j.rmed.2016.11.001

12. Humbert M et al. Pulmonary Arterial Hypertension in France. Results from a National Registry. Am J RespirCrit Care Med 2006;173:1023–1030.

13. Ventavis drug label. LSR-005775/10, 16.01.2017.

14. Escribano-Subias P et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry. EurRespir J 2012; 40: 596–603.

15. Peacock A et al. An epidemiological study of pulmonary arterial hypertension. EurRespir J 2007; 30: 104–109.

16. Kirson N et al. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 2011; 27: 1763–1768.

17. Pepke-Zaba J, Jansa P, Kim NH, Naeije R, Simonneau G. Chronic thromboembolic pulmonary hypertension: role of medical therapy. EurRespir J. 2013;41(4):985-90. doi: 10.1183/09031936.00201612.

18. Accessibility of medical care and drug provision for patients with rare diseases in the Russian Federation: realities and ways to solve the problems (results of medical and economic research for the period 2013-2015), Moscow, 2016.

19. Chazova I. E., O.A. Arkhipova, Z.S. Valiyeva, T.V. Martyniuk, S.N. Tips Pulmonary hypertension in Russia: first results of the national registry. Therapeutic Archive; 9: 56-64

20. Avdeev SN et al. Pulmonary Hypertension: A Guidance for doctors. Moscow, GEOTAR-Media, 2019; 8-56.

21. The Russian Federation Government Decree No. 403 of 2012 “On the procedure for maintaining the Federal Register of persons, suffering life-threatening and chronic progressive rare diseases that reduce the life span of people or their disability and its regional segment”.

22. Guidelines for the diagnosis and treatment of pulmonary hypertension. The task force for the diagnosis and treatment of pulmonary hypertension of the ECS and ERS, endorsed by the ISHLT. Eur Heart J 2009; 30: 2493—2537.

23. Ling Y., Johnson M.K., Kiely D.G. et al. Changing demographics,epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland. Am J RespirCrit Care Med2012; 186 (8): 790—796.

24. Badesch D.B., Raskob G.E., Elliott C.G. et al. Pulmonary Arterial Hypertension: Baseline Characteristics From the REVEAL Registry. Chest 2010; 137: 376—387.

25. Shapiro S., Traiger G. L., Turner M. et al. Differences in the Diagnosis, Treatment, and Outcome of Patients With Pulmonary Arterial Hypertension Enrolled in the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management. Chest 2012; 141 (2): 363—373.

26. Demographic Yearbook of Russia. 2010: Stat. Sb. Rosstat. M 2010; 525.

27. Barst RJ, McGoon M, Torbicki A, Sitbon O, Krowka MJ, Olschewski H, Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am CollCardiol, 2004; 43, 40S-7S. DOI: 10.1016/j.jacc.2004.02.032.

28. Chazova IY, Martynyuk TV et al. Pulmonary arterial hypertension: on the way from rational diagnosis to the choice of effective drug therapy. Systemic hypertension. 2013; 10(2): 57-69.

29. Fallah F. Recent Strategies in Treatment of Pulmonary Arterial Hypertension, A Review. Global Journal of Health Science, 2015; 7(4): 307-322. DOI: 10.5539/gjhs.v7n4p307

30. Taran I, Martynyuk T, Chazova I et al. Initial Riociguat Monotherapy and Transition from Sildenafil to Riociguat in Patients with Idiopathic Pulmonary Arterial Hypertension: Influence on Right Heart Remodeling and Right Ventricular–Pulmonary Arterial Coupling. Lung (2018) 196:745–753. https://doi.org/10.1007/s00408-018-0160-4

31. Data of the site «Ural Federal District». Available by reference: http://uralfo.gov.ru/ (available on 29.01.2019).

32. Guha M. First-in-class guanylate cyclase stimulator approved for PAH. Nat. Biotechnol. 2013; 31: 1064.

33. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263–73.

34. Ghofrani HA, Voswinckel R, Gall H et al. Riociguat for pulmonary hypertension. Future Cardiol 2010; 6: 155-166.

35. Hemnes AR, Champion HC. Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. Exp Rev CardiovascTher 2006; 4: 293–300.

36. M. M. Hoeper et al. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors. RespiratoryMedicine (2016), http://dx.doi.org/10.1016/j.rmed.2016.11.001

37. Ventavis drug label. LSR-005775/10, 16.01.2017.